Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair M Thompson

Showing results (131-140 of 195) with videos related to

Pageof 20
Sort By:
Elife|September 16, 2016
<i>TP53</i> drives invasion through expression of its Δ133p53β variantGilles Gadea, Nikola Arsic, Kenneth Fernandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast CancerPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic VariantJennifer K Litton, Marion E Scoggins, Kenneth R Hess, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 26, 2024
Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic reviewMichael Jiang, Kerry Avery, Rosina Ahmed, et al.
British Journal of Cancer|December 11, 2019
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metforminSimon R Lord, Jennifer M Collins, Wei-Chen Cheng, et al.
Academic Radiology|July 17, 2021
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRosalind P Candelaria, David A Spak, Gaiane M Rauch, et al.
Breast Cancer Research and Treatment|June 1, 2026
Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trialKamaria L Lee, Clinton Yam, Li Zhao, et al.
Science Signaling|March 5, 2024
eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancerWarapen Treekitkarnmongkol, Luisa M Solis, Deivendran Sankaran, et al.
JAMA Network Open|March 22, 2024
Intraoperative Evaluation of Breast Tissues During Breast Cancer Operations Using the MasSpec PenKyana Y Garza, Mary E King, Chandandeep Nagi, et al.
Pageof 20

Showing results (131-140 of 195) with videos related to

Sort By:
Pageof 20
Elife|September 16, 2016
<i>TP53</i> drives invasion through expression of its Δ133p53β variantGilles Gadea, Nikola Arsic, Kenneth Fernandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast CancerPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline <i>BRCA</i> Pathogenic VariantJennifer K Litton, Marion E Scoggins, Kenneth R Hess, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 26, 2024
Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic reviewMichael Jiang, Kerry Avery, Rosina Ahmed, et al.
British Journal of Cancer|December 11, 2019
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metforminSimon R Lord, Jennifer M Collins, Wei-Chen Cheng, et al.
Academic Radiology|July 17, 2021
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerRosalind P Candelaria, David A Spak, Gaiane M Rauch, et al.
Breast Cancer Research and Treatment|June 1, 2026
Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trialKamaria L Lee, Clinton Yam, Li Zhao, et al.
Science Signaling|March 5, 2024
eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancerWarapen Treekitkarnmongkol, Luisa M Solis, Deivendran Sankaran, et al.
JAMA Network Open|March 22, 2024
Intraoperative Evaluation of Breast Tissues During Breast Cancer Operations Using the MasSpec PenKyana Y Garza, Mary E King, Chandandeep Nagi, et al.
Pageof 20